Anzeige
Meldung des Tages: Deep-Value-Chance: 60 % Insideranteil – warum dieser Gold-Explorer als Geheimtipp gilt

Avidity Biosciences Aktie News

Aktie
WKN:  A2P5NK ISIN:  US05370A1088 US-Symbol:  RNA Branche:  Biotechnologie Land:  USA
72,93 $
+0,19 $
+0,26%
61,633 € 03.02.26
Depot/Watchlist
Marktkapitalisierung *
7,37 Mrd. €
Streubesitz
-
KGV
-16,07
Index-Zuordnung
-

Avidity Biosciences News

10.09.25 - PR Newswire
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People Living with DMD44
Avidity Biosciences' Del-zota Demonstrated Reversal of Disease Progression Across Key Functional Endpoints in EXPLORE44® and EXPLORE44-OLE™ Phase 1/2 Trial in People ...
27.08.25 - PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conferences
Avidity Biosciences to Participate in Upcoming Investor Conferences PR Newswire
07.08.25 - PR Newswire
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights
Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights PR Newswire
28.07.25 - PR Newswire
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-desiran) for Treatment of DM1 and Provides Guidance on Regulatory Submission
Avidity Biosciences Announces Completion of Enrollment for HARBOR™, the First Global Phase 3 Trial of Delpacibart Etedesiran (del-​desiran) for Treatment of DM1 and Provides ...
23.07.25 - PR Newswire
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 ...
11.06.25 - PR Newswire
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD ...
09.06.25 - PR Newswire
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in ...
09.06.25 - PR Newswire
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in ...
21.05.25 - PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.05.25 - PR Newswire
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights PR Newswire
06.05.25 - PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire
21.04.25 - PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
08.04.25 - PR Newswire
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-​desiran) for Treatment of Myotonic Dystrophy Type 1 PR Newswire
01.04.25 - PR Newswire
Avidity Biosciences to Participate in Upcoming Investor Conference
Avidity Biosciences to Participate in Upcoming Investor Conference PR Newswire
31.03.25 - PR Newswire
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral ...
21.03.25 - PR Newswire
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire
17.03.25 - PR Newswire
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in ...
12.03.25 - PR Newswire
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference PR Newswire
28.02.25 - PR Newswire
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases PR Newswire
27.02.25 - PR Newswire
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights
Avidity Biosciences Reports Fourth Quarter 2024 Financial Results and Recent Highlights PR Newswire

Newssuche

Videos

newspaper
03.02.26
2026 02 03 17 34 Trendjumper Einführung
Zunächst inormieren wir unsere Stammkunden bezüglich des bevorstehenden Seminars und bieten für ... Mehr »